

# Insider Intelligence

## Insider Intelligence Trade Alert 1/23/22

**W** Insider Intelligence

# \*\*Buy Alert: MAIA Biotechnology Inc (NASDAQ: MAIA)\*\* Price at alert: \$4.67 Buy Limit: \$4.99 Stop Limit: \$3.50

Another Insider Intelligence trade idea coming at you.

This week, we're issuing a buy alert on MAIA Biotechnology Corporation.

MAIA is a clinical-stage pharmaceutical company that specializes in telomeretargeting cancer treatments.

What are telomeres you ask? They're the little "caps" on the end of your chromosomes.


When your cells divide, these telomeres separate, to create a brand new copy of chromosomes for your two new cells.

As you age, these telomeres wear out, which causes your cellular health to decline.

A lot of research has actually been done on the role of using telomere therapies to increase our longevity.

The idea being that if worn out telomeres lead to worn out cells, repairing our telomeres can actually increase our lifespan on a cellular level.

Market Press Media is a publishing company. It does not act as a personal investment advisor for any specific individual. Past



own due diligence.

But in MAIA's case, they're focusing on telomeres and their role in cancer.

According to MAIA's website, telomeres play a key role in the proliferation and reproductive immortality of cancer cells.

MAIA's main drug THIO targets these telomeres and degrades them. Essentially "uncapping" the chromosomes inside the cancerous cells.

In theory, this would cause the chromosomes to break apart and the cancer cells to implode.

THIO is currently in Phase 2 of its FDA clinical trials. Testing is slated to begin in the second half of 2023.


For biotech companies, successful trials can often result in major stock moves.

Which may be why insiders are loading up on shares prior to the start of the Phase 2 study.

Over the last month, CEO Vlad Vitoc has bought up 4,000 shares in two separate transactions.

SEC Form 4																			
FORM 4 U						INITED STATES SECURITIES AND EXCHANGE COMMISSION Weatington, D.C. 20549										OMB APPROVAL			
Check this box if no longer subject to 5 obligations may continue. See instru	Section 16, Parm 4 or action 1(b).	r Form			S	0.0000000000	T OF CHAN	IGES IN	BENE Socurties	EFICIA Exchange	Act of 1934	ERSHIP				DMB Numbet; Istimated average iours per response		3236 Q28 Q	
1: Name and Address of Reporting Person <sup>4</sup> ELLIN ROBERT S						issuer Name an iveOne, Inc				(Chec	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner								
C/O LIVEONE, INC.						3. Date of Earliest Transaction (Month/Day/Year) 11/16/2022								X Officer (give title below) Other (specify below) CEO & Chairman					
(Street) BEVERLY HILLS CA 90212					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	State)	a	Clip)		Table I -	Non-Dariya	tive Securitie	. Acquire	d Dien	oeed of	or Bona	Scially Owner	4		30.				
1. Title of Security (Instr. 3)	2	. Transaction	2A. Deamed Execution Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (ins 5)			Beneficially Owned Following		ving (D) or	ionship Form: Direct Indirect (i) (Instr. 4)	7. Natura of Indires Beneficial						
					0	(Month/Day/Year)	if any (Month/Day/Year)	Code	V	Amount		(A) or (D)	Price	Reported Transaction( and 4)	iction(s) (	nstr. 3		Ownership (Instr. 4)	
Common Stock, \$0.001 par valu	0				10.4	11/16/2022		P			5,000	Α	\$0.7264 <sup>(3)</sup>	2,05	4,666		D		
Common Stock, \$0.001 par valu	e				- ST						a			17,5	52,984		-1	See footnotes <sup>(2)</sup> (2)(00)	
					Table		ve Securities / ts, calls, warra												
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	tercise Date Execution 0 of (Month/Day/Year) If any otive (Month/Day	Execution Date,		iction Code	Securitie	er of Derivative s Acquired (A) or t of (D) (Instr. 3, 4 an	6. Date Excretisable Expiration Date		e and	Security (Instr. 3 and 4)		ies Underlying Der	3 Derivative Derivative Security (Instr		<ol> <li>Number of derivative Securities Beneficially Owned Following</li> </ol>	y (Instr. 4)	11. Noture of Indirec Beneficial Connershi (Instr. 4)	
				Code	v	(4)	(D)	Dote Exercis	able D	Expiration Nate			Amount or Nu of Shares	nber	Reporter Transact (Instr. 4)				

Market Press Media is a publishing company. It does not act as a personal investment advisor for any specific individual. Past



own due diligence.

#### **W** Insider Intelligence


FORM 4					UNITED	D STATE	ES SECURI			OMB APPROVAL								
Check this box if no longer subject 5 obligations may continue. See In:	STAT	3/3327/952	F OF CHAN		ENEFICI	877 S S S S S S S S S S S S S S S S S S			CMB Number: Estimated average burden hours per response:									
	000000000					Files p	ursuant to Section or Section 30(h) o	the investment	Company Act of	yr 1940 Yr 1940								
1. Name and Address of Reporting Person <sup>*</sup> ELLIN ROBERT S						er Name and One, Inc.	Ticker or Trading : [ LVO ]	9ymbol			5. Re (Che	5. Relationship of Reporting Person(s) to issuer (Check all applicable) X Director X 10% Owner						
(Les) C/O LIVEONE, INC. 269 SOUTH BEVERLY DRI	(Fist) /E, SUITE 1450	(M	vlickfle)		3. Date / 11/21/2		ransaction (Month)	Day"Year)				X Officer (give title below) Other (specify CEO & Chairman						
(Sweet) BEVERLY HILLS	са	9	0212		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Inc	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(2	čip)															
1. Title of Security (Instr. 3)				Та	2. Tran	n-Derivat	ive Securities 2A. Deemed	3. Transaction	and the second second		ficially Owner	Contract of the local division of the	d 5. Amount of Securit	ine 6	Ownership Form: Direct	7. Nature of Indirect		
					Date (Month	h/Day/Year)	Execution Date, if any (Month/Day/Year)	(Instr. 8) Code V	aj Amoun	Amount (A) or (D) Price		Price	Beneficially Owned Following Reported Transaction(s) (Instr. and 4)		7) or Indirect (1) (Instr. 4)	Beneficial Ownership (Indit: 4)		
Common Stock, \$0.001 par va	ue				11/2	21/2022		P		25,000	A	\$0.6675(1)	2,079.6	66	D			
Common Stock, \$0.001 par va	Common Stock, S0.001 par value					21/2022		p		10,000	Α	\$0.680917	2,089,6	66	D			
Common Stock, \$0.001 par value													17,552,5	184	I	See footnotes <sup>(3)</sup> (4)(2)(3)		
				8			e Securities A s, calls, warra											
1. Title of Derivative Security (Instr. 3)	or Exercise Date Price of (Month/Day/Year) Derivative		r Exercise Date Execution Date, rice of (Month/Dwy/Year) If any		Execution Date, (in Any/Year) If any		an Code	5. Number Securities	of Derivative Acquired (A) or of (D) (instr. 3, 4 an	6. Date Exer Expiration D	cisable and ale	7. Title and	7. Title and Amount of Securities Unde Security (Instr. 3 and 4)		ivative 8. Price of Derivative Security (Instr.)	9. Kumber of derivative Securities Seneticially Owned Felle	Form: Direct (D) or indirect (I) (instr. 4)	11. Nature of indirec Beneficial Ownershi (instr. 4)
	Service	Code		~	109	Date Expiration Exercisable Date Title			Amount or Numb		mber	Reported Transaction ( (matr. 4)	2.47					

Board of Directors-member Stan Smith has scooped up 10,000 shares over the course of four transactions (only one pictured here).

FO	RM 4	UNITED STATE	INITED STATES SECURITIES AND EXCHANGE COMMISSION							OMB APPROVAL						
Check this box if no longer su 5 obligations may continue. S	bject to Section 16. Form 4 or Forr ee Instruction 1(b).	n	Filed p	T OF CHAN	16(a) of the	BENE	EFICIAL OWN			mber: d average burden r response:	3235-0287 0.5					
i ritario ana ritario do or rieporting i eroori				2. Issuer Name and Ticker or Trading Symbol <u>MAIA Biotechnology, Inc.</u> [ MAIA ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) 444 WEST LAKE STRE	(First) ET,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/20/2022 Officer (give title below) Other (specify below)									cify below)				
(Street) CHICAGO	IL	60606	4. If Amendment, D	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)														
			Table I - Non-Derivat	tive Securities	Acquire	d, Disp	osed of, or Bene	ficially Owne	bd							
I. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired 5)	(A) or Disposed	Of (D) (Instr. 3, 4 and	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirec Beneficial Ownership (Instr. 4				
				if any (Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)						
Common Stock			12/20/2022		P		4,048	A	\$3.53(1)(2)	507,376	I	See Footnote <sup>(2)</sup>				
					1		1	1				1				

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

Market Press Media is a publishing company. It does not act as a personal investment advisor for any specific individual. Past



own due diligence.

----- 3

### Insider Intelligence —

#### And fellow board member Christian Luput has been buying in as well.

SEC Form 4

	FORM 4		UNITED STATI		TIES AN ashington, D.	OMB APPROVAL						
Check this box if no lor 5 obligations may conti	nger subject to Section 16. Form 4 or Form inue. See Instruction 1(b).		Filed p	T OF CHAN	GES IN	BENE	EFICIAL OWN Exchange Act of 1934 any Act of 1940	ERSHIP			umber: ed average burden er response:	3235-0287 0.5
1. Name and Address of Luput Cristian	2. Issuer Name and MAIA Biotec			I			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) 444 WEST LAKE S	(First) TREET, SUITE 1700	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/13/2023 Officer (give title below) Other (specify below)									acity below)
(Street) CHICAGO	IL	4. If Amendment, D	ate of Original File	d (Month/Day	/Year)		12 A. M. C.	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)								i an difficult e 12 anning e 1963 an	h Chanair Anna an Air Anna an Air ann	
		Т	able I - Non-Derivat	tive Securities	Acquire	d, Dispo	osed of, or Benet	icially Owne	d			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year) If any		3. Transacti (instr. 8)	on Code	4. Securities Acquired 5)	(A) or Disposed C	of (D) (Instr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			(Month/Day/Year)	(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	and 4)	, 	Gwnersnip (mstr. 4)
Common Stock			01/13/2023		Р		504	A	\$3.88(1)(2)	278,572	D	

Considering these insider buys plus the progression of THIO through the FDA trial pipeline, we're adding this trade idea to our model portfolio.

On important thing to note:

MAIA recently IPO'ed over the summer. So, without a significant track record to go off of, this is a riskier trade than most.

Like we say every time, when it comes to any investment, never risk anything that you're not willing to lose!


Any questions?

Feel free to reach out and let us know!

To your wealth,

Alex Reid, Founder Insider Intelligence

Market Press Media is a publishing company. It does not act as a personal investment advisor for any specific individual. Past



.....**4**